Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study
•-Management of metastatic rectal adenocarcinoma is multidisciplinary and complex.•-Induction triplet chemotherapy is effective on primary site and metastases.•-Induction chemotherapy is associated with a high rate of objective response rate.•Metastases resection allows for prolonged survival.•Progn...
Gespeichert in:
| Veröffentlicht in: | Clinics and research in hepatology and gastroenterology 2025-01, Vol.49 (1), p.102514, Article 102514 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 102514 |
| container_title | Clinics and research in hepatology and gastroenterology |
| container_volume | 49 |
| creator | Dabout, Victoire Mineur, Laurent Tougeron, David Malicot, Karine Le Gallois, Claire Phelip, Jean Marc Turpin, Anthony Cohen, Romain Demoustier, Benedicte Hautefeuille, Vincent Locher, Christophe Levaché, Charles-Briac Mitry, Emmanuel Lecomte, Thierry Brocard, Fabien Hassid, Deborah Porte, Marie Breysacher, Gilles Lagasse, Jean-Paul Lepage, Côme Valéry, Marine Bachet, Jean-Baptiste |
| description | •-Management of metastatic rectal adenocarcinoma is multidisciplinary and complex.•-Induction triplet chemotherapy is effective on primary site and metastases.•-Induction chemotherapy is associated with a high rate of objective response rate.•Metastases resection allows for prolonged survival.•Prognostic value of KRAS/BRAF mutations appears similar for rectal and colon cancers.
The management of synchronous metastatic rectal cancer (SMRC) is complex and multimodal, involving chemotherapy, surgery and/or radiotherapy. The aim of this study was firstly to confirm the efficacy of the induction FOLFIRINOX, and secondly to evaluate the different therapeutic strategies and outcomes of patients.
This French study combined data from a prospective FFCD trial and a multicenter cohort. Patients included had SMRC and had undergone induction triplet chemotherapy. Two groups of patients were defined according to the resectability of metastases at baseline: resectable (Res) and unresectable (URes). The primary endpoint was the objective response rate.
146 patients were included in 16 French centers and 65 patients in the FFCD1102 trial. In overall population the median age of patients was 59 years, 86% of tumors were of the lower or middle rectum, 33% were well-differentiated, 53% were RAS mutated and 7% BRAF mutated. Triplet induction was associated with 80% of objective response and 92% of disease control. After the induction phase, 69% and 48% of patients of Res and URes groups underwent rectal surgery, and secondary metastases resection was done in 79% and 39% of patients, respectively. Median overall survival (OS) for Res was 56.3 months (95% CI: 22.54-NA). Median OS for URes who had or not secondary metastases resection were 45.1 months (95% CI: 39.89-NA) and 21.1 months (95% CI 17.31–27.1), respectively. Patients with BRAF mutated tumors were more likely to have unresectable disease, and had worse survivals than the patients with RAS mutated or RAS/BRAF wild-type.
Triplet induction chemotherapy is a treatment of choice in selected patients with SMRC, allowing to adapt the therapeutic strategy to the response and invasiveness of the various sites.
The management of metastatic rectal cancer is essentially based on three main therapeutic approaches: surgery, radiotherapy/chemoradiotherapy and chemotherapy. Induction triplet chemotherapy appears as a good choice for fit and young patients. It allows to adapt the therapeutic strategy to the response and invasiveness of |
| doi_str_mv | 10.1016/j.clinre.2024.102514 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3146777324</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2210740124002353</els_id><sourcerecordid>3146777324</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2381-907b89a8a066998d5dfaa60d88298f9b30efb6a4f84f6f035192336ddd3ec5d43</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVpaEKSf1CKjj3UW31Zli-FsM2mgUAuLfQmtNKY1WJLriS37L-vFqc5VgxIzLzvjOZB6D0lG0qo_Hzc2NGHBBtGmKgp1lLxBl0xRknTCfrz7eub0Et0m_OR1CNaojr6Dl3yXnai7cgVKo_BLbb4GHBJfh6hYHuAKZYDJDOfsA94NsVDKBn_8eWAE9hiRmwchGhNsj7EyWATHM6nYA8phrhkPEExuQbkT7WG7x7un5vdbvsV57K40w26GMyY4fblvkY_dvfft9-ap-eHx-3dU2MZV7TpSbdXvVGGSNn3yrVuMEYSpxTr1dDvOYFhL40YlBjkQHhLe8a5dM5xsK0T_Bp9XPvOKf5aIBc9-WxhHE2A-kvNqZBd13F2lopValPMOcGg5-Qnk06aEn1Gro96Ra7PyPWKvNo-vExY9hO4V9M_wFXwZRVA3fO3h6SzrTQtOH8mqV30_5_wF8C9lOE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146777324</pqid></control><display><type>article</type><title>Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Dabout, Victoire ; Mineur, Laurent ; Tougeron, David ; Malicot, Karine Le ; Gallois, Claire ; Phelip, Jean Marc ; Turpin, Anthony ; Cohen, Romain ; Demoustier, Benedicte ; Hautefeuille, Vincent ; Locher, Christophe ; Levaché, Charles-Briac ; Mitry, Emmanuel ; Lecomte, Thierry ; Brocard, Fabien ; Hassid, Deborah ; Porte, Marie ; Breysacher, Gilles ; Lagasse, Jean-Paul ; Lepage, Côme ; Valéry, Marine ; Bachet, Jean-Baptiste</creator><creatorcontrib>Dabout, Victoire ; Mineur, Laurent ; Tougeron, David ; Malicot, Karine Le ; Gallois, Claire ; Phelip, Jean Marc ; Turpin, Anthony ; Cohen, Romain ; Demoustier, Benedicte ; Hautefeuille, Vincent ; Locher, Christophe ; Levaché, Charles-Briac ; Mitry, Emmanuel ; Lecomte, Thierry ; Brocard, Fabien ; Hassid, Deborah ; Porte, Marie ; Breysacher, Gilles ; Lagasse, Jean-Paul ; Lepage, Côme ; Valéry, Marine ; Bachet, Jean-Baptiste</creatorcontrib><description>•-Management of metastatic rectal adenocarcinoma is multidisciplinary and complex.•-Induction triplet chemotherapy is effective on primary site and metastases.•-Induction chemotherapy is associated with a high rate of objective response rate.•Metastases resection allows for prolonged survival.•Prognostic value of KRAS/BRAF mutations appears similar for rectal and colon cancers.
The management of synchronous metastatic rectal cancer (SMRC) is complex and multimodal, involving chemotherapy, surgery and/or radiotherapy. The aim of this study was firstly to confirm the efficacy of the induction FOLFIRINOX, and secondly to evaluate the different therapeutic strategies and outcomes of patients.
This French study combined data from a prospective FFCD trial and a multicenter cohort. Patients included had SMRC and had undergone induction triplet chemotherapy. Two groups of patients were defined according to the resectability of metastases at baseline: resectable (Res) and unresectable (URes). The primary endpoint was the objective response rate.
146 patients were included in 16 French centers and 65 patients in the FFCD1102 trial. In overall population the median age of patients was 59 years, 86% of tumors were of the lower or middle rectum, 33% were well-differentiated, 53% were RAS mutated and 7% BRAF mutated. Triplet induction was associated with 80% of objective response and 92% of disease control. After the induction phase, 69% and 48% of patients of Res and URes groups underwent rectal surgery, and secondary metastases resection was done in 79% and 39% of patients, respectively. Median overall survival (OS) for Res was 56.3 months (95% CI: 22.54-NA). Median OS for URes who had or not secondary metastases resection were 45.1 months (95% CI: 39.89-NA) and 21.1 months (95% CI 17.31–27.1), respectively. Patients with BRAF mutated tumors were more likely to have unresectable disease, and had worse survivals than the patients with RAS mutated or RAS/BRAF wild-type.
Triplet induction chemotherapy is a treatment of choice in selected patients with SMRC, allowing to adapt the therapeutic strategy to the response and invasiveness of the various sites.
The management of metastatic rectal cancer is essentially based on three main therapeutic approaches: surgery, radiotherapy/chemoradiotherapy and chemotherapy. Induction triplet chemotherapy appears as a good choice for fit and young patients. It allows to adapt the therapeutic strategy to the response and invasiveness of the various sites. In this study dedicated to patients undergoing treatment for rectal cancer with synchronous metastases, FOLFIRINOX-based induction chemotherapy was associated with objective response rate of 77% and disease control rate of 92%. These results are similar with those of the FFCD 1102 trial and confirm the efficacy of induction chemotherapy with FOLFIRINOX with or without targeted therapy in these patients in daily routine practice. Surgery for metastases is a key factor in determining patient's outcome and triplet induction chemotherapy, associated with high response rates, enables a significant percentage of patients to undergo surgery and appears therefore to be a treatment of choice, particularly for patients whose disease is unresectable at baseline.</description><identifier>ISSN: 2210-7401</identifier><identifier>ISSN: 2210-741X</identifier><identifier>EISSN: 2210-741X</identifier><identifier>DOI: 10.1016/j.clinre.2024.102514</identifier><identifier>PMID: 39674570</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - mortality ; Adenocarcinoma - secondary ; Adenocarcinoma - therapy ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; BRAF ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - therapeutic use ; FOLFIRINOX ; Humans ; Induction Chemotherapy ; Irinotecan - therapeutic use ; KRAS ; Leucovorin - administration & dosage ; Leucovorin - therapeutic use ; Male ; Metastatic rectal cancer ; Middle Aged ; Neoplasm Metastasis ; Oxaliplatin - administration & dosage ; Oxaliplatin - therapeutic use ; Prospective Studies ; Rectal Neoplasms - drug therapy ; Rectal Neoplasms - pathology ; Rectal Neoplasms - therapy ; Resectability ; Synchronous metastases</subject><ispartof>Clinics and research in hepatology and gastroenterology, 2025-01, Vol.49 (1), p.102514, Article 102514</ispartof><rights>2024 Elsevier Masson SAS</rights><rights>Copyright © 2024 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2381-907b89a8a066998d5dfaa60d88298f9b30efb6a4f84f6f035192336ddd3ec5d43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2210740124002353$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39674570$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dabout, Victoire</creatorcontrib><creatorcontrib>Mineur, Laurent</creatorcontrib><creatorcontrib>Tougeron, David</creatorcontrib><creatorcontrib>Malicot, Karine Le</creatorcontrib><creatorcontrib>Gallois, Claire</creatorcontrib><creatorcontrib>Phelip, Jean Marc</creatorcontrib><creatorcontrib>Turpin, Anthony</creatorcontrib><creatorcontrib>Cohen, Romain</creatorcontrib><creatorcontrib>Demoustier, Benedicte</creatorcontrib><creatorcontrib>Hautefeuille, Vincent</creatorcontrib><creatorcontrib>Locher, Christophe</creatorcontrib><creatorcontrib>Levaché, Charles-Briac</creatorcontrib><creatorcontrib>Mitry, Emmanuel</creatorcontrib><creatorcontrib>Lecomte, Thierry</creatorcontrib><creatorcontrib>Brocard, Fabien</creatorcontrib><creatorcontrib>Hassid, Deborah</creatorcontrib><creatorcontrib>Porte, Marie</creatorcontrib><creatorcontrib>Breysacher, Gilles</creatorcontrib><creatorcontrib>Lagasse, Jean-Paul</creatorcontrib><creatorcontrib>Lepage, Côme</creatorcontrib><creatorcontrib>Valéry, Marine</creatorcontrib><creatorcontrib>Bachet, Jean-Baptiste</creatorcontrib><title>Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study</title><title>Clinics and research in hepatology and gastroenterology</title><addtitle>Clin Res Hepatol Gastroenterol</addtitle><description>•-Management of metastatic rectal adenocarcinoma is multidisciplinary and complex.•-Induction triplet chemotherapy is effective on primary site and metastases.•-Induction chemotherapy is associated with a high rate of objective response rate.•Metastases resection allows for prolonged survival.•Prognostic value of KRAS/BRAF mutations appears similar for rectal and colon cancers.
The management of synchronous metastatic rectal cancer (SMRC) is complex and multimodal, involving chemotherapy, surgery and/or radiotherapy. The aim of this study was firstly to confirm the efficacy of the induction FOLFIRINOX, and secondly to evaluate the different therapeutic strategies and outcomes of patients.
This French study combined data from a prospective FFCD trial and a multicenter cohort. Patients included had SMRC and had undergone induction triplet chemotherapy. Two groups of patients were defined according to the resectability of metastases at baseline: resectable (Res) and unresectable (URes). The primary endpoint was the objective response rate.
146 patients were included in 16 French centers and 65 patients in the FFCD1102 trial. In overall population the median age of patients was 59 years, 86% of tumors were of the lower or middle rectum, 33% were well-differentiated, 53% were RAS mutated and 7% BRAF mutated. Triplet induction was associated with 80% of objective response and 92% of disease control. After the induction phase, 69% and 48% of patients of Res and URes groups underwent rectal surgery, and secondary metastases resection was done in 79% and 39% of patients, respectively. Median overall survival (OS) for Res was 56.3 months (95% CI: 22.54-NA). Median OS for URes who had or not secondary metastases resection were 45.1 months (95% CI: 39.89-NA) and 21.1 months (95% CI 17.31–27.1), respectively. Patients with BRAF mutated tumors were more likely to have unresectable disease, and had worse survivals than the patients with RAS mutated or RAS/BRAF wild-type.
Triplet induction chemotherapy is a treatment of choice in selected patients with SMRC, allowing to adapt the therapeutic strategy to the response and invasiveness of the various sites.
The management of metastatic rectal cancer is essentially based on three main therapeutic approaches: surgery, radiotherapy/chemoradiotherapy and chemotherapy. Induction triplet chemotherapy appears as a good choice for fit and young patients. It allows to adapt the therapeutic strategy to the response and invasiveness of the various sites. In this study dedicated to patients undergoing treatment for rectal cancer with synchronous metastases, FOLFIRINOX-based induction chemotherapy was associated with objective response rate of 77% and disease control rate of 92%. These results are similar with those of the FFCD 1102 trial and confirm the efficacy of induction chemotherapy with FOLFIRINOX with or without targeted therapy in these patients in daily routine practice. Surgery for metastases is a key factor in determining patient's outcome and triplet induction chemotherapy, associated with high response rates, enables a significant percentage of patients to undergo surgery and appears therefore to be a treatment of choice, particularly for patients whose disease is unresectable at baseline.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - secondary</subject><subject>Adenocarcinoma - therapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>BRAF</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - therapeutic use</subject><subject>FOLFIRINOX</subject><subject>Humans</subject><subject>Induction Chemotherapy</subject><subject>Irinotecan - therapeutic use</subject><subject>KRAS</subject><subject>Leucovorin - administration & dosage</subject><subject>Leucovorin - therapeutic use</subject><subject>Male</subject><subject>Metastatic rectal cancer</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Oxaliplatin - administration & dosage</subject><subject>Oxaliplatin - therapeutic use</subject><subject>Prospective Studies</subject><subject>Rectal Neoplasms - drug therapy</subject><subject>Rectal Neoplasms - pathology</subject><subject>Rectal Neoplasms - therapy</subject><subject>Resectability</subject><subject>Synchronous metastases</subject><issn>2210-7401</issn><issn>2210-741X</issn><issn>2210-741X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1r3DAQhkVpaEKSf1CKjj3UW31Zli-FsM2mgUAuLfQmtNKY1WJLriS37L-vFqc5VgxIzLzvjOZB6D0lG0qo_Hzc2NGHBBtGmKgp1lLxBl0xRknTCfrz7eub0Et0m_OR1CNaojr6Dl3yXnai7cgVKo_BLbb4GHBJfh6hYHuAKZYDJDOfsA94NsVDKBn_8eWAE9hiRmwchGhNsj7EyWATHM6nYA8phrhkPEExuQbkT7WG7x7un5vdbvsV57K40w26GMyY4fblvkY_dvfft9-ap-eHx-3dU2MZV7TpSbdXvVGGSNn3yrVuMEYSpxTr1dDvOYFhL40YlBjkQHhLe8a5dM5xsK0T_Bp9XPvOKf5aIBc9-WxhHE2A-kvNqZBd13F2lopValPMOcGg5-Qnk06aEn1Gro96Ra7PyPWKvNo-vExY9hO4V9M_wFXwZRVA3fO3h6SzrTQtOH8mqV30_5_wF8C9lOE</recordid><startdate>202501</startdate><enddate>202501</enddate><creator>Dabout, Victoire</creator><creator>Mineur, Laurent</creator><creator>Tougeron, David</creator><creator>Malicot, Karine Le</creator><creator>Gallois, Claire</creator><creator>Phelip, Jean Marc</creator><creator>Turpin, Anthony</creator><creator>Cohen, Romain</creator><creator>Demoustier, Benedicte</creator><creator>Hautefeuille, Vincent</creator><creator>Locher, Christophe</creator><creator>Levaché, Charles-Briac</creator><creator>Mitry, Emmanuel</creator><creator>Lecomte, Thierry</creator><creator>Brocard, Fabien</creator><creator>Hassid, Deborah</creator><creator>Porte, Marie</creator><creator>Breysacher, Gilles</creator><creator>Lagasse, Jean-Paul</creator><creator>Lepage, Côme</creator><creator>Valéry, Marine</creator><creator>Bachet, Jean-Baptiste</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202501</creationdate><title>Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study</title><author>Dabout, Victoire ; Mineur, Laurent ; Tougeron, David ; Malicot, Karine Le ; Gallois, Claire ; Phelip, Jean Marc ; Turpin, Anthony ; Cohen, Romain ; Demoustier, Benedicte ; Hautefeuille, Vincent ; Locher, Christophe ; Levaché, Charles-Briac ; Mitry, Emmanuel ; Lecomte, Thierry ; Brocard, Fabien ; Hassid, Deborah ; Porte, Marie ; Breysacher, Gilles ; Lagasse, Jean-Paul ; Lepage, Côme ; Valéry, Marine ; Bachet, Jean-Baptiste</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2381-907b89a8a066998d5dfaa60d88298f9b30efb6a4f84f6f035192336ddd3ec5d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - secondary</topic><topic>Adenocarcinoma - therapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>BRAF</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - therapeutic use</topic><topic>FOLFIRINOX</topic><topic>Humans</topic><topic>Induction Chemotherapy</topic><topic>Irinotecan - therapeutic use</topic><topic>KRAS</topic><topic>Leucovorin - administration & dosage</topic><topic>Leucovorin - therapeutic use</topic><topic>Male</topic><topic>Metastatic rectal cancer</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Oxaliplatin - administration & dosage</topic><topic>Oxaliplatin - therapeutic use</topic><topic>Prospective Studies</topic><topic>Rectal Neoplasms - drug therapy</topic><topic>Rectal Neoplasms - pathology</topic><topic>Rectal Neoplasms - therapy</topic><topic>Resectability</topic><topic>Synchronous metastases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dabout, Victoire</creatorcontrib><creatorcontrib>Mineur, Laurent</creatorcontrib><creatorcontrib>Tougeron, David</creatorcontrib><creatorcontrib>Malicot, Karine Le</creatorcontrib><creatorcontrib>Gallois, Claire</creatorcontrib><creatorcontrib>Phelip, Jean Marc</creatorcontrib><creatorcontrib>Turpin, Anthony</creatorcontrib><creatorcontrib>Cohen, Romain</creatorcontrib><creatorcontrib>Demoustier, Benedicte</creatorcontrib><creatorcontrib>Hautefeuille, Vincent</creatorcontrib><creatorcontrib>Locher, Christophe</creatorcontrib><creatorcontrib>Levaché, Charles-Briac</creatorcontrib><creatorcontrib>Mitry, Emmanuel</creatorcontrib><creatorcontrib>Lecomte, Thierry</creatorcontrib><creatorcontrib>Brocard, Fabien</creatorcontrib><creatorcontrib>Hassid, Deborah</creatorcontrib><creatorcontrib>Porte, Marie</creatorcontrib><creatorcontrib>Breysacher, Gilles</creatorcontrib><creatorcontrib>Lagasse, Jean-Paul</creatorcontrib><creatorcontrib>Lepage, Côme</creatorcontrib><creatorcontrib>Valéry, Marine</creatorcontrib><creatorcontrib>Bachet, Jean-Baptiste</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinics and research in hepatology and gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dabout, Victoire</au><au>Mineur, Laurent</au><au>Tougeron, David</au><au>Malicot, Karine Le</au><au>Gallois, Claire</au><au>Phelip, Jean Marc</au><au>Turpin, Anthony</au><au>Cohen, Romain</au><au>Demoustier, Benedicte</au><au>Hautefeuille, Vincent</au><au>Locher, Christophe</au><au>Levaché, Charles-Briac</au><au>Mitry, Emmanuel</au><au>Lecomte, Thierry</au><au>Brocard, Fabien</au><au>Hassid, Deborah</au><au>Porte, Marie</au><au>Breysacher, Gilles</au><au>Lagasse, Jean-Paul</au><au>Lepage, Côme</au><au>Valéry, Marine</au><au>Bachet, Jean-Baptiste</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study</atitle><jtitle>Clinics and research in hepatology and gastroenterology</jtitle><addtitle>Clin Res Hepatol Gastroenterol</addtitle><date>2025-01</date><risdate>2025</risdate><volume>49</volume><issue>1</issue><spage>102514</spage><pages>102514-</pages><artnum>102514</artnum><issn>2210-7401</issn><issn>2210-741X</issn><eissn>2210-741X</eissn><abstract>•-Management of metastatic rectal adenocarcinoma is multidisciplinary and complex.•-Induction triplet chemotherapy is effective on primary site and metastases.•-Induction chemotherapy is associated with a high rate of objective response rate.•Metastases resection allows for prolonged survival.•Prognostic value of KRAS/BRAF mutations appears similar for rectal and colon cancers.
The management of synchronous metastatic rectal cancer (SMRC) is complex and multimodal, involving chemotherapy, surgery and/or radiotherapy. The aim of this study was firstly to confirm the efficacy of the induction FOLFIRINOX, and secondly to evaluate the different therapeutic strategies and outcomes of patients.
This French study combined data from a prospective FFCD trial and a multicenter cohort. Patients included had SMRC and had undergone induction triplet chemotherapy. Two groups of patients were defined according to the resectability of metastases at baseline: resectable (Res) and unresectable (URes). The primary endpoint was the objective response rate.
146 patients were included in 16 French centers and 65 patients in the FFCD1102 trial. In overall population the median age of patients was 59 years, 86% of tumors were of the lower or middle rectum, 33% were well-differentiated, 53% were RAS mutated and 7% BRAF mutated. Triplet induction was associated with 80% of objective response and 92% of disease control. After the induction phase, 69% and 48% of patients of Res and URes groups underwent rectal surgery, and secondary metastases resection was done in 79% and 39% of patients, respectively. Median overall survival (OS) for Res was 56.3 months (95% CI: 22.54-NA). Median OS for URes who had or not secondary metastases resection were 45.1 months (95% CI: 39.89-NA) and 21.1 months (95% CI 17.31–27.1), respectively. Patients with BRAF mutated tumors were more likely to have unresectable disease, and had worse survivals than the patients with RAS mutated or RAS/BRAF wild-type.
Triplet induction chemotherapy is a treatment of choice in selected patients with SMRC, allowing to adapt the therapeutic strategy to the response and invasiveness of the various sites.
The management of metastatic rectal cancer is essentially based on three main therapeutic approaches: surgery, radiotherapy/chemoradiotherapy and chemotherapy. Induction triplet chemotherapy appears as a good choice for fit and young patients. It allows to adapt the therapeutic strategy to the response and invasiveness of the various sites. In this study dedicated to patients undergoing treatment for rectal cancer with synchronous metastases, FOLFIRINOX-based induction chemotherapy was associated with objective response rate of 77% and disease control rate of 92%. These results are similar with those of the FFCD 1102 trial and confirm the efficacy of induction chemotherapy with FOLFIRINOX with or without targeted therapy in these patients in daily routine practice. Surgery for metastases is a key factor in determining patient's outcome and triplet induction chemotherapy, associated with high response rates, enables a significant percentage of patients to undergo surgery and appears therefore to be a treatment of choice, particularly for patients whose disease is unresectable at baseline.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>39674570</pmid><doi>10.1016/j.clinre.2024.102514</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2210-7401 |
| ispartof | Clinics and research in hepatology and gastroenterology, 2025-01, Vol.49 (1), p.102514, Article 102514 |
| issn | 2210-7401 2210-741X 2210-741X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3146777324 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - secondary Adenocarcinoma - therapy Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use BRAF Female Fluorouracil - administration & dosage Fluorouracil - therapeutic use FOLFIRINOX Humans Induction Chemotherapy Irinotecan - therapeutic use KRAS Leucovorin - administration & dosage Leucovorin - therapeutic use Male Metastatic rectal cancer Middle Aged Neoplasm Metastasis Oxaliplatin - administration & dosage Oxaliplatin - therapeutic use Prospective Studies Rectal Neoplasms - drug therapy Rectal Neoplasms - pathology Rectal Neoplasms - therapy Resectability Synchronous metastases |
| title | Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T07%3A00%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Induction%20triplet%20chemotherapy%20in%20patients%20with%20rectal%20adenocarcinoma%20and%20synchronous%20metastases,%20an%20AGEO-FFCD%20study&rft.jtitle=Clinics%20and%20research%20in%20hepatology%20and%20gastroenterology&rft.au=Dabout,%20Victoire&rft.date=2025-01&rft.volume=49&rft.issue=1&rft.spage=102514&rft.pages=102514-&rft.artnum=102514&rft.issn=2210-7401&rft.eissn=2210-741X&rft_id=info:doi/10.1016/j.clinre.2024.102514&rft_dat=%3Cproquest_cross%3E3146777324%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3146777324&rft_id=info:pmid/39674570&rft_els_id=S2210740124002353&rfr_iscdi=true |